Skip to Content

Safety of using bispecific antibody for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is the frontrunner when it comes to targeted therapy, however data on the efficacy and safety of therapeutic bispecific antibodies are extremely limited.
In this MEDtalk, Arnon P. Kater presents the phase 1b/2 trial Epcore CLL-1 investigating the dose-limiting toxicities of a bispecific CD3/CD20 antibody drug – epcoritamab. According to results, dose levels up to 48 mg of epcoritamab are well-tolerated, and bispecific drugs might be a candidate for future combination with other drugs in the treatment of patients with R/R CLL.

Arnon P. Kater

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top